- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26,000 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Boynton Beach, Florida • Jacksonville, Florida + 18 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 456906, Placebo, Semaglutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 31
- States / cities
- Huntington Park, California • Los Angeles, California • Northridge, California + 27 more
- Conditions
- Atrial Fibrillation, Obesity, Overweight
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 71
- States / cities
- Anniston, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
- Interventions
- Calcium-HMB Plus Vitamin D3, Matching placebo
- Dietary Supplement · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Obesity, Overweight, Cigarette Smoking
- Interventions
- semaglutide 2.4mg, Placebo, Nicotine Replacement Therapy (NRT, nicotine patch), Brief Smoking Cessation Counseling
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Austin, Texas • Houston, Texas
- Conditions
- Obesity
- Interventions
- Nimacimab injection, Nimacimab placebo injection, semaglutide injection, Nimacimab 300 mg injection
- Biological · Combination Product
- Lead sponsor
- Skye Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Anniston, Alabama • Walnut Creek, California • Waterbury, Connecticut + 13 more
- Conditions
- Asthma
- Interventions
- Semaglutide Pen Injector 2.4mg weekly, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetic Kidney Disease, Type 1 Diabetes
- Interventions
- Semaglutide, Placebo
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Seattle, Washington • Spokane, Washington
- Conditions
- Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
- Interventions
- Semaglutide Auto-Injector, Placebo
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Obesity & Overweight, Diabetes (DM)
- Interventions
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 622 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 19
- States / cities
- Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
- Conditions
- Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
- Interventions
- Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • St Louis, Missouri
- Conditions
- Alcohol-related Liver Disease
- Interventions
- NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more
- Conditions
- Obesity, Type 2 Diabetes
- Interventions
- Cagrisema, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
- Conditions
- Metabolism and Nutrition Disorder, Overweight or Obesity
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,961 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 39
- States / cities
- Anniston, Alabama • Anaheim, California • Lomita, California + 32 more
- Conditions
- Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
- Interventions
- Semaglutide, Placebo, Counselling on healthy lifestyle intervention
- Drug · Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Obese, Overweight or Obesity
- Interventions
- Bimagrumab, Semaglutide, Placebo
- Biological · Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Oral semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts